
華領醫藥

(2552)

30, 201


Trial #
Drugs
Disease indication
Study type
Pre-clinical
Phase I
Phase II
Phase III
NDA
HMM0301
HMM0302
HMM0311
HMM0312
HMM0109
HMM0110
HMM0111
HMM0112
T2D
+ DPP-4
+ SGLT-2
PK/PD & DDI

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

	[illegible] 30,		
	201	%	201	%
	’000		’000	
		%		%
		%		%
		%		%
		%		%
		%		%

[illegible]

- [illegible]
- [illegible]


	30, 201 '000	30, 201 '000

	[illegible] 201 '000	30, 201 '000
[illegible]	( )	( )
[illegible]	( )	
[illegible]		
[illegible]	( )	

[illegible] [illegible]

[illegible]

[illegible] ( ) f [illegible]



[illegible]

	30,	
	201	201
	’000	’000
	(%)	(%)
	( )	( )
	( )	( )
		( )
	( )	( )
		( )
	( )	( )
	( )	( )
	( )	( )
	( )	( )
	( )	( )
	( )	( )

	f 30, 201 '000 ( )	f 31, 201 '000 ( )

f	f
30,	31,
201	201
’000	’000
(%)	(%)
	( )
% %	

1.

2.

3.

		30,
	201	201
	’000	’000
	( )	( )

4.

	30,	
	201	201
	’000	’000
	( )	( )
		( )

5.

	30,	
	201	201
	’000	’000
	( )	( )

7.

.

		30,
	201	201
	’000	’000
	( )	( )
	( )	( )

		30,
	201	201
	( )	( )

7 -734.20

11. [illegible]

	f 30, 201 '000 ([illegible])	f 31, 201 '000 ([illegible])
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

12. [illegible]

[illegible] % [illegible] % [illegible] % [